Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Biomotion Sciences Warrant (SLXNW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: SLXNW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -59.62% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.12 | 52 Weeks Range 0.01 - 0.18 | Updated Date 06/5/2025 |
52 Weeks Range 0.01 - 0.18 | Updated Date 06/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -193.54% | Return on Equity (TTM) -116.66% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 996278 |
Shares Outstanding - | Shares Floating 996278 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Biomotion Sciences Warrant
Company Overview
History and Background
There is no public information available about a company called Biomotion Sciences Warrant. It is possible this is a privately held company, the information does not exist, or the company has a different name on the stock market.
Core Business Areas
Leadership and Structure
There is no public information available about a company called Biomotion Sciences Warrant.
Top Products and Market Share
Key Offerings
Market Dynamics
Industry Overview
Without information on the company, the industry it operates in cannot be identified.
Positioning
Without information on the company, its market position cannot be identified.
Total Addressable Market (TAM)
Without information on the company, its TAM cannot be determined.
Upturn SWOT Analysis
Strengths
Weaknesses
Opportunities
Threats
Competitors and Market Share
Key Competitors
Competitive Landscape
Without information on the company, its competitive advantages and disadvantages cannot be evaluated.
Growth Trajectory and Initiatives
Historical Growth: Without information on the company, no historical growth trends can be discussed.
Future Projections: Without information on the company, no future projections can be provided.
Recent Initiatives: Without information on the company, no recent strategic initiatives can be highlighted.
Summary
Without any available information, it is not possible to summarize the company's strengths, weaknesses, or outlook. Further research would be needed if a US company with this name actually exists.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Publicly available data sources were searched, but no information was found.
Disclaimers:
The information provided is based on publicly available data. Due to the limited data found, the analysis is incomplete and should not be used for investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biomotion Sciences Warrant
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2024-08-16 | Chairman & CEO Mr. Ilan Hadar M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 11 | Website https://silexion.com |
Full time employees 11 | Website https://silexion.com | ||
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.